Inari Medical, Inc. (NARI)

Market Cap	3.13B
Revenue (ttm)	520.66M
Net Income (ttm)	-23.62M
Shares Out	58.14M
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,023,962
Open	55.78
Previous Close	55.20
Day's Range	53.75 - 56.10
52-Week Range	36.73 - 71.85
Beta	1.01
Analysts	Buy
Price Target	66.40 (+23.35%)
Earnings Date	Jul 30, 2024

About NARI

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embol...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 22, 2020
• Employees: 1,300
• Stock Exchange: NASDAQ
• Ticker Symbol: NARI

Financial Performance

In 2023, Inari Medical's revenue was $493.63 million, an increase of 28.73% compared to the previous year's $383.47 million. Losses were -$1.64 million, -94.41% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for NARI stock is "Buy." The 12-month stock price forecast is $66.4, which is an increase of 23.35% from the latest price.

Price Target

$66.4

(23.35% upside)

Analyst Consensus: Buy